Brief: Repare Therapeutics Inc - Initial Tresr Data Provide Clinical Proof Of Concept, Validate Sniprx Platform For Molecular Selection Of Tumors For Therapy With Rp-3500

Repare Therapeutics

08/10/2021 20:59

Oct 8 (Reuters) - Repare Therapeutics Inc  RPTX.O :
    * REPARE THERAPEUTICS PRESENTS PRELIMINARY PHASE 1
MONOTHERAPY
CLINICAL DATA FROM ONGOING FIRST-IN-HUMAN PHASE 1/2 TRESR STUDY
OF RP-3500 IN SOLID TUMORS
    * REPARE THERAPEUTICS INC - INITIAL TRESR DATA PROVIDE
CLINICAL
PROOF OF CONCEPT, VALIDATE SNIPRX PLATFORM FOR MOLECULAR
SELECTION OF TUMORS FOR THERAPY WITH RP-3500
    * REPARE THERAPEUTICS INC - PRELIMINARY DATA SHOW THAT
MONOTHERAPY
RP-3500 IS SAFE AND WELL TOLERATED

Source text for Eikon:  urn:newsml:reuters.com:*:nBw8ftR8Za
Further company coverage:  RPTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))